Published in J Thorac Oncol on July 01, 2009
Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med (2012) 5.21
Tumour heterogeneity in the clinic. Nature (2013) 3.92
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist (2012) 1.53
Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res (2011) 1.38
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res (2015) 1.29
Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One (2011) 1.21
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One (2014) 1.14
Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol (2013) 1.05
Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol (2012) 1.04
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol (2012) 1.00
Pleural involvement in lung cancer. J Thorac Dis (2015) 0.94
Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget (2015) 0.93
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol (2012) 0.90
Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One (2011) 0.90
EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol (2012) 0.90
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res (2015) 0.89
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. J Cancer Res Clin Oncol (2010) 0.89
Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One (2014) 0.88
From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int (2011) 0.86
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey. J Pathol Transl Med (2015) 0.86
Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch (2012) 0.85
Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer. PLoS One (2013) 0.80
Aberrant loss of dickkopf-3 in gastric cancer: can it predict lymph node metastasis preoperatively? World J Surg (2015) 0.79
LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study. Medicine (Baltimore) (2015) 0.77
Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report. J Med Case Rep (2011) 0.77
Usefulness of high suction pressure for sufficient tissue collection during endobronchial ultrasound guided transbronchial needle aspiration. PLoS One (2013) 0.77
Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer. PLoS One (2016) 0.75
IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Ann Surg (2016) 0.75
Commentary on tumor heterogeneity. Transl Lung Cancer Res (2016) 0.75
An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). Cancers (Basel) (2011) 0.75
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. Onco Targets Ther (2017) 0.75
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2008) 6.91
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol (2012) 3.90
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol (2013) 3.63
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol (2012) 3.44
Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov (2012) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology (2006) 3.02
Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology (2007) 2.91
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol (2005) 2.90
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol (2003) 2.64
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.62
HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci (2006) 2.53
Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. Chest (2013) 2.52
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res (2005) 2.49
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol (2007) 2.48
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res (2009) 2.35
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res (2008) 2.28
New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol (2013) 2.25
A comparative analysis of video-assisted mediastinoscopy and conventional mediastinoscopy. Ann Thorac Surg (2011) 2.23
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19
Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology (2005) 2.19
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis (2008) 2.17
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. J Thorac Oncol (2015) 2.17
Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res (2009) 2.12
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res (2009) 2.06
Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol (2004) 2.02
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res (2008) 2.00
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol (2010) 1.95
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol (2013) 1.93
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol (2010) 1.86
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol (2012) 1.76